Clene Inc. CLNN Archives - Page 9 of 9

TuesdayOct 10, 2023 2:10 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is featured in the latest Bell2Bell Podcast release. During the segment, podcast host Stuart Smith discusses the company with Clene president and CEO Rob Etherington, who explains Clene’s business model and provides an overview of recent developments, which provide hope to those affected by neurodegenerative conditions. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. “Clene spends every waking moment working on amyotrophic lateral sclerosis (‘ALS’), a devastating neurodegenerative condition,” said Clene president…

ThursdayOct 05, 2023 11:29 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S.…

ThursdaySep 28, 2023 11:49 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the…

ThursdaySep 28, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…

MondaySep 25, 2023 10:53 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. are reporting on long-term follow-up data for participants in the HEALEY ALS Platform Trial; patients in the study were treated with CNM-Au8(R) 30mg for up to 133 weeks. According to the announcement, data from 59 patients shows prolonged life with 49% decreased risk of death for participants compared to PRO-ACT matched placebo over long-term follow-up; data also showed prolonged life with 59% decreased risk of death for participants in an integrated meta-analysis across HEALEY ALS Platform Trial and RESCUE-ALS Trial with CNM-Au8 30mg compared to PRO-ACT matched placebo over long-term follow-up.…

Site Search

Company Search

Tag: Clene Inc. CLNN

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial

Market Basics

Newsletter Publishers

Public Companies